Bioventus Q2 FY26 GAAP EPS rises to $0.47; revenue increases 4% to $153.2 million

• Bioventus posted Q2 revenue of USD 153.2 million, up 4% from a year earlier.
• GAAP diluted EPS more than doubled to USD 0.47, helped by removal of a USD 24.6 million deferred-tax valuation allowance.
• Non-GAAP diluted EPS edged up 5% to USD 0.22; adjusted EBITDA rose 4% to USD 35.3 million.
• Cash from operations totaled USD 19.9 million; a USD 20 million discretionary term-loan principal prepayment was made during the quarter.
• Board initiated a strategic alternatives review after an unsolicited acquisition proposal; 2026 guidance was reaffirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050730PRIMZONEFULLFEED9803964) on August 05, 2026, and is solely responsible for the information contained therein.